Erste Group Bank Comments on Gilead Sciences FY2027 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities research analysts at Erste Group Bank issued their FY2027 earnings estimates for Gilead Sciences in a research report issued on Wednesday, February 18th. Erste Group Bank analyst H. Engel anticipates that the biopharmaceutical company will post earnings per share of $9.67 for the year. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share.

A number of other research analysts also recently issued reports on the company. Argus raised their price target on Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $160.00 price objective on shares of Gilead Sciences in a research note on Wednesday, February 11th. Needham & Company LLC lifted their target price on shares of Gilead Sciences from $140.00 to $170.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. HSBC upped their price objective on Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research report on Wednesday, December 10th. Finally, TD Cowen lifted their target price on shares of Gilead Sciences from $145.00 to $160.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Twenty-three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $155.44.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $151.40 on Monday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.68 and a quick ratio of 1.31. Gilead Sciences has a 12 month low of $93.37 and a 12 month high of $157.29. The firm has a market capitalization of $187.84 billion, a PE ratio of 22.36, a price-to-earnings-growth ratio of 2.01 and a beta of 0.36. The business’s fifty day moving average price is $133.47 and its 200 day moving average price is $123.81.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Vermillion & White Wealth Management Group LLC grew its position in shares of Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 85 shares during the last quarter. GoalVest Advisory LLC increased its holdings in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares in the last quarter. Corundum Trust Company INC bought a new stake in shares of Gilead Sciences during the third quarter worth $26,000. Quattro Advisors LLC bought a new stake in Gilead Sciences during the 4th quarter worth about $26,000. Finally, Ares Financial Consulting LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $28,000. Institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00. Following the completion of the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at $76,504,230. This trade represents a 16.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the transaction, the chief financial officer directly owned 150,503 shares in the company, valued at $18,709,027.93. The trade was a 1.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 319,891 shares of company stock valued at $45,091,556 in the last quarter. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. Gilead Sciences’s payout ratio is 46.68%.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 earnings beat and firm guidance: Gilead reported $1.86 EPS vs. $1.83 est. and $7.93B revenue (above estimates) and set FY‑2026 EPS guidance of $8.45–$8.85 — a catalyst for re-rating. Analyst Reactions Post‑Earnings
• Positive Sentiment: Argus raised its price target to $165 and kept a Buy rating, adding analyst-driven upside (~mid-single digits vs. current levels). Argus PT Raise
• Positive Sentiment: Mizuho lifted its target to $170 and kept an Outperform rating, supporting a higher consensus valuation and momentum for buy‑side flows. Mizuho PT Raise
• Neutral Sentiment: Barclays initiated coverage with an Equal‑Weight rating and $155 target — neither a strong buy nor a sell signal, but it provides fresh institutional coverage. Barclays Coverage
• Neutral Sentiment: Broader analyst and media coverage (Zacks, Yahoo, Benzinga retrospectives) is keeping GILD in focus for retail/institutional investors; these pieces inform positioning but are mixed in directional impact. Zacks Coverage
• Neutral Sentiment: Short‑interest data in the feed looks anomalous/zeroed out and provides no clear sell pressure signal at present (data likely noisy).
• Negative Sentiment: Insider selling: CFO Andrew Dickinson sold 3,000 shares (~$154.43 avg price) — a small amount but negative for sentiment when combined with other insider moves. CFO Form 4
• Negative Sentiment: Material insider sale: Johanna Mercier sold 28,000 shares (~$154.44 avg), an ~18.9% reduction in her holding — a larger ticket that can weigh on investor confidence. Mercier Form 4
• Negative Sentiment: “Time to take profits” / rating downgrade commentary is circulating, which can trigger short‑term selling from momentum traders. Seeking Alpha Take‑Profits Piece

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.